D. Boral Capital Reaffirms Buy Rating for Enlivex Therapeutics (NASDAQ:ENLV)

Enlivex Therapeutics (NASDAQ:ENLV)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $13.00 target price on the stock.

ENLV has been the topic of several other reports. EF Hutton Acquisition Co. I upgraded shares of Enlivex Therapeutics to a “strong-buy” rating in a report on Tuesday, August 27th. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Enlivex Therapeutics in a report on Friday, September 27th.

Enlivex Therapeutics Stock Performance

Shares of NASDAQ ENLV opened at $1.30 on Tuesday. Enlivex Therapeutics has a 12-month low of $0.81 and a 12-month high of $4.59. The stock has a market cap of $27.83 million, a PE ratio of -1.33 and a beta of 1.01. The company has a 50-day moving average of $1.34 and a 200 day moving average of $1.35.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in shares of Enlivex Therapeutics in the second quarter valued at about $35,000. Sigma Investment Counselors Inc. purchased a new position in Enlivex Therapeutics during the 3rd quarter valued at about $50,000. Finally, Armistice Capital LLC purchased a new position in Enlivex Therapeutics during the 2nd quarter valued at about $2,415,000. 1.02% of the stock is owned by hedge funds and other institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.